Circulating endothelial cell levels in psoriatic patients and their modification after an anti-TNF-alpha (Etanercept) treatment

Journal of the European Academy of Dermatology and Venereology

Volumn 28, Issue 5, 2014, Pages 590-596

  De Simone, C ^a   Caldarola, G ^a   Coco, V ^a   Palumbo, S ^b   Pocino, K ^b   Sgambato, A ^a   Maiorino, A ^a   Corbi, M ^a   Sandri, M T ^c   Vendittelli, F ^b   Capoluongo, E ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ETANERCEPT; VASCULOTROPIN; IMMUNOGLOBULIN G; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIASIS; PSORIASIS SEVERITY INDEX; PSORIATIC ARTHRITIS; ANTAGONISTS AND INHIBITORS; BLOOD; CASE CONTROL STUDY; IMMUNOMAGNETIC SEPARATION; MIDDLE AGED;

ADULT; CASE-CONTROL STUDIES; ENDOTHELIAL CELLS; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOMAGNETIC SEPARATION; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84899480792     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12140     Document Type: Article

References (46)

1. de Rie MA, Goedkoop AY, Bos JD,. Overview of psoriasis. Dermatol Ther 2004; 17: 341-349.
2. Robinson D Jr, Hackett M, Wong J, et al,. Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001-2002. Curr Med Res Opin 2006; 22: 989-1000.
3. Gottlieb AB, Chao C, Dann F,. Psoriasis comorbidities. J Dermatolog Treat 2008; 19: 5-21.
4. Reed WB, Becker SW, Rhode R, Heiskell CL,. Psoriasis and psoriatic arthritis. A clinicopathologic conference. Arch Dermatol 1961; 99: 86.
5. Gelfand JM, Neimann AL, Shin DB, et al,. Risk of myocardialinfarction in patients with psoriasis. JAMA 2006; 296: 1735-1741.
6. Henseler T, Christophers E,. Disease concomitance in psoriasis. J Am Acad Dermatol 1995; 32: 982-986.
7. Ena P, Madeddu P, Glorioso N, et al,. High prevalence of cardiovascular diseases and enhanced activity of the renin-angiotensin system in psoriatic patients. Acta Cardiol 1985; 40: 199-205.
8. McDonald CJ, Calabresi P,. Psoriasis and occlusive vascular disease. Br J Dermatol 1978; 99: 469-475.
9. Pearce DJ, Morrison AE, Higgins KB, et al,. The comorbid state of psoriasis patients in a university dermatology practice. J Dermatolog Treat 2005; 16: 319-323.
10. Mehta NN, Yu Y, Pinnelas R, et al,. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med 2011; 124: 775.
11. Mallbris L, Akre O, Granath F, et al,. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004; 19: 225-230.
12. Naldi L, Parazzini F, Brevi A, et al,. Family history, smoking habits, alcohol consumption and risk of psoriasis. Br J Dermatol 1992; 127: 212-217.
13. Gudjonsson JE, Karason A, Runarsdottir EH, et al,. Distinct clinical differences between HLA-Cw0602 positive and negative psoriasis patients-an analysis of 1019 HLA-C- and HLA-B-typed patients. J Invest Dermatol 2006; 126: 740-745.
14. Campalani E, Allen MH, Fairhurst D, et al,. Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. Br J Dermatol 2006; 154: 345-352.
15. Matsuura E, Kobayashi K, Lopez LR,. Atherosclerosis in autoimmune diseases. Curr Rheumatol Rep 2009; 11: 61-69.
16. Boehncke WH, Boehncke S, Tobin AM, Kirby B,. The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 2011; 20: 303-307.
17. Martyn-Simmons CL, Ranawaka RR, Chowienczyk P, et al,. A prospective case-controlled cohort study of endothelial function in patients with moderate to severe psoriasis. Br J Dermatol 2011; 164: 26-32.
18. De Simone C, Di Giorgio A, Sisto T, et al,. Endothelial dysfunction in psoriasis patients: cross-sectional case-control study. Eur J Dermatol 2011; 21: 510-514.
19. Mallbris L, Pernow J, Ståhle M,. Endothelial function and inflammatory activity in patients with recent onset of severe plaque psoriasis. Open Dermatol J 2008; 2: 64-68.
20. Jensen PR, Zachariae C, Hansen P, Skov L,. Normal endothelial function in patients with mild-to-moderate psoriasis: a case-control study. Acta Derm Venereol 2011; 91: 516-520.
21. Erdbruegger U, Haubitz M, Woywodt A,. Circulating endothelial cells: a novel marker of endothelial damage. Clin Chim Acta 2006; 373: 17-26.
22. Bardin N, Anfosso F, Massé JM, et al,. Identification of CD146 as a component of the endothelial junction involved in the control of cell-cell cohesion. Blood 2001; 98: 3677-3684.
23. Arenberger P, Buchtova'L, Hladovec J., Increase of endothelaemia in psoriasis. Acta Derm Venereol 1993; 73: 35-36.
24. Sochorova R, Svecova D, Sinka L, Rybarova L,. Increased endothelemia as an indirect marker of changes in the blood vessel endothelium in psoriasis. J Eur Acad Dermatol Venereol 2004; 18: 556-559.
25. Batycka-Baran A, Paprocka M, Krawczenko A, et al,. Increased number of circulating endothelial cells (CECs) in patients with psoriasis -preliminary report. J Eur Acad Dermatol Venereol 2012; Aug 7. doi: 10.1111/j.1468-3083.2012. 04671.x. [Epub ahead of print]
26. Strijbos MH, Gratama JW, Kraan J, et al,. Circulating endothelial cells in oncology: pitfalls and promises. Br J Cancer 2008; 98: 1731-1735.
27. Milardi D, Grande G, Giampietro A, et al,. Circulating Endothelial Cells as Marker of Endothelial Damage in Male Hypogonadism. J Androl 2012; 33: 1291-1297.
28. Bertolini F, Shaked Y, Mancuso P, Kerbel RS,. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 2006; 6: 835-845.
29. Fredriksson T, Petterson U,. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244.
30. Lee KW, Lip GY, Tayebjee M, et al,. Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes. Blood 2005; 105: 526-532.
31. Koc M, Richards HB, Bihorac A, et al,. Circulating endothelial cells are associated with future vascular events in hemodialysis patients. Kidney Int 2005; 67: 1078-1083.
32. McClung JA, Naseer N, Saleem M, et al,. Circulating endothelial cells are elevated in patients with type 2 diabetes mellitus independently of HbA(1)c. Diabetologia 2005; 48: 345-350.
33. Perticone F, Ceravolo R, Pujia A, et al,. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104: 191-196.
34. Schmieder RE, Weihprecht H, Schobel H, et al,. Is endothelial function of the radial artery altered in human essential hypertension? Am J Hypertens 1997; 10: 323-331.
35. Yiu KH, Yeung CK, Chan HT, et al,. Increased arterial stiffness in patients with psoriasis is associated with active systemic inflammation. Br J Dermatol 2011; 164: 514-520.
36. Sergeant A, Makrygeorgou A, Chan WC, Thorrat A, Burden D,. C-reactive protein in psoriasis. Br J Dermatol 2008; 158: 417-419.
37. Foster W, Shantsila E, Carruthers D, Lip GY, Blann AD,. Circulating endothelial cells and rheumatoid arthritis: relationship with plasma markers of endothelial damage/dysfunction. Rheumatology (Oxford) 2009; 48: 285-288.
38. Galarraga B, Belch JJ, Pullar T, et al,. Clinical improvement in rheumatoid arthritis is associated with healthier microvascular function in patients who respond to antirheumatic therapy. Rheumatol 2010; 37: 521-528.
39. Avgerinou G, Tousoulis D, Siasos G, et al,. Anti-tumor necrosis factor α treatment with adalimumab improves significantly endothelial function and decreases inflammatory process in patients with chronic psoriasis. Int J Cardiol 2011; 151: 382-383.
40. Kondo S, Ueno H, Hashimoto J, et al,. Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy. BMC Cancer 2012; 12: 268.
41. Gritti G, Cortelezzi A, Bucciarelli P, et al,. Circulating and progenitor endothelial cells are abnormal in patients with different types of von Willebrand disease and correlate with markers of angiogenesis. Am J Hematol 2011; 86: 650-656.
42. Szepietowski J, Wasik F, Bielicka E, et al,. Soluble E-selectin serum levels correlate with disease activity in psoriatic patients. Clin Exp Dermatol 1999; 24: 33-36.
43. Nadar S, Lip GYH, Blann AD,. Circulating endothelial cells in acute ischaemic stroke. Thromb Haemost 2005; 94: 707-712.
44. Boos CJ, Balakrishnan B, Blann AD, Lip GY,. The relationship of circulating endothelial cells to plasma indices of endothelial damage/dysfunction and apoptosis in acute coronary syndromes: implications for prognosis. J Thromb Haemost 2008; 6: 1841-1850.
45. Oh IY, Yoon CH, Hur J, et al,. Involvement of E-selectin in recruitment of endothelial progenitor cells and angiogenesis in ischemic muscle. Blood 2007; 110: 3891-3899.
46. Batycka-Baran A, Paprocka M, Krawczenko A, et al,. Reduced number of circulating endothelial progenitor cells (CD133 + /KDR+) in patients with plaque psoriasis. Dermatology 2012; 225: 88-92.